Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Shareholder Meeting (October 2023)
13 slides from Rhythm Biosciences's shareholder meeting presentation, Oct 10, 2023
Slide 1: 2023 AGM Investor Presentation
2023 AGM INVESTOR PRESENTATION 10 OCTOBER 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Introduction
Introduction “ Rhythm Biosciences is committed to saving lives through early detection of cancers using simple and accurate diagnostic technology ” ➢ Early detection is critical to improving patient outcomes and reducing the global burden of cancer; ➢ Developing alternative screening solutions for s
Slide 4: Board and Management
Board and Management Otto Buttula Trevor Lockett PhD Sue MacLeman Dr Rachel David Lou Panaccio Executive Chairman Technical Director Independent, Non Exec Director Non Exec Director •Extensive financial, investment, IT •Former Theme Leader Colorectal Deputy Chair •Currently the Chief Executive •Chai
Slide 5: Company Overview
Company Overview Capital Structure at 9 October 2023 ASX Code RHY Share Price $0.32 Disruptive Technology Global Capacity Shares on Issue 221.1 M Unlisted Options 12.2 M An alternative to current screening Manufacturing capability for our target Market Capitalisation $92.8 M methods through markets
Slide 6: Why we are here and why ColoSTAT?
BURDEN OF COLORECTAL CANCER Why we are here and why ColoSTAT®? Global burden in 2020: 1.93 million new cases and ~940,000 deaths, CRC is the 5-year survival rates for those diagnosed at an early second largest cause of cancer death1 stage* of CRC are over 90%,4 but sub-optimal participation rate is
Slide 7: ColoSTAT last 12 months (FY23)
ColoSTAT® last 12 months (FY23) Regulatory TGA application withdrawn. June 23 guidance document for External focus ISO 13485 and IVDD to IVDR has increased requirements Australia/UK advisory meeting with Key Opinion Leaders Renewed patents across 21 countries International recognition for ColoSTAT®
Slide 8: Platform Technology Expansion – Stage 1
Platform Technology Expansion – Stage 1 Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Initiation: Formulation: Design & Development: Final Validation: Product Launch & Opportunity and Concept and Verification, Validation, Product Launch Post-Launch Risk Analysis Feasibility & Clinical Trials Preparation A
Slide 9: Regulatory Submissions
Regulatory Submissions Pathway to Regulatory Success CE / CA IVDD IVDR TGA • Self-declared product • To be assessed by regulators • ARTG applications withdrawn • Marketing authorisation in Europe, UK (notified body) March 23 and New Zealand • ColoSTAT® European approval for • Detailed clinical repor
Slide 10: Rhythm's Focus on Market Entry
Rhythm’s Focus on Market Entry Market Populatio Age – Screening Screening Screening Unscreened Screening Screening Incidence n Population Method Participation Population/ Population Opportunity of CRC Rate Opportunity based on based on RHY001 RHY001 (40 to <85 yrs) (40 to <85 yrs) FIT, Europe 455.1
Slide 11: ColoSTAT - UK Go-to-Market
ColoSTAT® - UK Go-to-Market Work with Strategic Partners ✓ Market Overview Publications ✓ Market Access Medical Individuals ✓ Regulatory ColoSTAT® Community Endorsement ColoSTAT® alternative to current screening methods aged ≥ 40 tested for CRC Approval Local Clinical Validation Ongoing post ✓ Marke
Slide 12: Rhythm's Focus for FY24
Rhythm’s Focus for FY 24 H1 H2 ✓ Established UK Subsidiary • Launch ColoSTAT® in additional markets ✓ Completed Stage 1 of Breast pipeline project • Expand Automation Project ✓ Expanded and renewed management team • Sign additional contracts ✓ UK Clinical Advisory Group commenced to evaluate • Ongoi
Slide 13: ColoSTAT - patented in over 20 countries
ColoSTAT® - patented in over 20 countries U.K. U.S. France Belgium Australia Luxembourg N.Z. Austria Spain Italy Sweden Finland Germany Liechtenstein Norway Japan China Netherlands Denmark Switzerland Ireland Brazil Portugal EXTERNAL USE 13
Rhythm Biosciences — Shareholder Meeting (October 2023) on 6ix